nivolumab,ipilimumab
bms
['rectal', 'solid tumor']
 major pathologic response is defined as residual viable tumor of less than or equal to 10%, and it is used as a surrogate end point for survival for patients with resectable solid tumors after neoadjuvant chemotherapy (sometimes + crt like rectal cancer tnt)
Co-founder @MassiveBio | Director of Oncology Research @capitalhealthnj | Entrepreneur | #genomics #Tech #AI #trials #cancer #startup #unicorn #A17a -My Opinion